Novogen (NASDAQ:KZIA) Given New $40.00 Price Target at BTIG Research

Novogen (NASDAQ:KZIA) had its price objective upped by equities researchers at BTIG Research from $34.00 to $40.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research’s price target points to a potential upside of 211.62% from the stock’s current price.

Several other brokerages also recently issued reports on KZIA. Lake Street Capital assumed coverage on shares of Novogen in a report on Thursday, June 11th. They issued a “buy” rating and a $32.00 price target on the stock. Canaccord Genuity Group initiated coverage on Novogen in a research report on Thursday, August 13th. They set a “buy” rating and a $29.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Novogen in a research note on Friday, July 17th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.33.

Novogen Price Performance

NASDAQ KZIA traded down $0.93 during trading hours on Tuesday, reaching $12.84. The company’s stock had a trading volume of 343,611 shares, compared to its average volume of 219,009. The company’s 50-day moving average is $13.47 and its two-hundred day moving average is $11.31. Novogen has a fifty-two week low of $4.86 and a fifty-two week high of $17.40.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.